22.03.2010 10:00:00
|
AngioDynamics Welcomes Recently Published Book on Irreversible Electroporation and Patient Experiences
AngioDynamics (NASDAQ:ANGO) today welcomed the publication of the book "Irreversible Electroporation,” published by Springer Berlin Heidelberg.
The book is edited by Boris Rubinsky, a Professor of the Graduate School at the University of California, Berkeley.
The book’s chapters include one by the book’s editor and Dr. Gary Onik of the School of Medicine at the University of Central Florida, titled, ‘Irreversible Electroporation: First Patient Experience Focal Therapy of Prostate Cancer,’ and another by Dr. Kenneth Thomson of The Alfred hospital in Melbourne Australia titled, ‘Human Experience with Irreversible Electroporation.’
Other chapters written by a number of different authors address a wide range of topics, including an analysis of tissue electroporation as a bioelectric phenomenon and insight from models into the mechanism of irreversible electroporation in cells.
About AngioDynamics
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
The views and opinions expressed in the publication "Irreversible Electroporation” are those of the authors alone and do not necessarily represent the views or opinions of AngioDynamics.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AngioDynamics Inc.mehr Nachrichten
27.11.24 |
NASDAQ Composite Index-Wert AngioDynamics-Aktie: So viel Verlust hätte eine AngioDynamics-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
20.11.24 |
NASDAQ Composite Index-Titel AngioDynamics-Aktie: So viel Verlust wäre bei einem Investment in AngioDynamics von vor einem Jahr angefallen (finanzen.at) | |
13.11.24 |
NASDAQ Composite Index-Papier AngioDynamics-Aktie: So viel hätte eine Investition in AngioDynamics von vor 10 Jahren gekostet (finanzen.at) | |
12.11.24 |
Börse New York: NASDAQ Composite präsentiert sich schlussendlich schwächer (finanzen.at) | |
12.11.24 |
Dienstagshandel in New York: NASDAQ Composite liegt am Dienstagnachmittag im Minus (finanzen.at) | |
12.11.24 |
Verluste in New York: NASDAQ Composite verliert am Mittag (finanzen.at) | |
12.11.24 |
Aufschläge in New York: NASDAQ Composite startet mit Gewinnen (finanzen.at) | |
11.11.24 |
Handel in New York: NASDAQ Composite beendet den Montagshandel in der Gewinnzone (finanzen.at) |
Analysen zu AngioDynamics Inc.mehr Analysen
Aktien in diesem Artikel
AngioDynamics Inc. | 6,55 | 0,00% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 060,48 | -0,60% |